期刊文献+

HPLC法测定马来酸阿法替尼片的溶出度

Dissolution of Afatinib Dimaleate Tablets by HPLC
下载PDF
导出
摘要 目的应用高效液相色谱法建立马来酸阿法替尼片溶出度的测定方法。方法溶出度采用桨法,以pH 4.0磷酸盐缓冲液900m L为溶出介质,转速为75r·min^(-1)。用十八烷基硅烷键合硅胶为填充剂(CAPCELL PAK MGⅡ,250mm×4.6mm,5μm),以0.05mol·L^(-1)甲酸铵(甲酸调节pH至4.5)-甲醇(31∶69)为流动相。流速为1.0m L·min^(-1);检测波长为254nm,柱温为35℃,进样量10μL。结果马来酸阿法替尼在0.37~149.9μg·m L^(-1)浓度范围内线性关系良好(R2=0.999),精密度良好(RSD=0.52%),溶液在12h内稳定(RSD=0.54%),平均回收率为99.8%(RSD=0.30%)。结论该方法准确、简便。 OBJECTIVE To establish a high performance liquid chromatography (HPLC) method for the disso- lution of afatinib dimaleate tablets. METHODS Paddle method was used in the dissolution test with 900mL of pH 4. 0 buffer as the medium at the rotation speed of 75r · min-1. An CAPCELL PAK MG II C18 column(250mm×4.6mm,5μm) was used for the separation. The mobile phase consisted of 0. 05mol · L-1ammonium formate (pH was adjusted to 4. 5 with formic acid)and methanol (31:69 ) at the flow rate of 1.0mL·min-1, the detective wavelength was 254nm, and the column temperature was 40℃. The injection volume was 10μL. RESULTS Afatinib dimaleate showed a good linear relationship within the range of 0. 37 - 149.9μg · mL-1 ( R2 = 0. 999 ) , the precisions and 12- hour stability were satisfactory with RSD 0. 52% and 0. 54% respectively ,the average recovery was 99.8% (RSD = 0. 30% ). CONCLUSION This method is accurate, fast.
出处 《海峡药学》 2017年第6期42-45,共4页 Strait Pharmaceutical Journal
关键词 马来酸阿法替尼片 溶出度 高效液相色谱法 Afatinib dimaleate tablets Dissolution HPLC
  • 相关文献

参考文献2

二级参考文献23

  • 1中国药典[S].2010年版.二部.附录ⅨJ.
  • 2American Cancer Society.Global Cancer Facts & Figures 2013[R].3rd Edition.Atlanta:American Cancer Society,2013.
  • 3D'Angelo SP,Pietanza MC,Johnson ML,et al.Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas[J].J Clin Oncol,2011,29(15);2066-2070.doi:10.12(X)/JC0.2010.32.6181.
  • 4Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemother- apy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802):a multicentre,open-label,randomised, phase 3 study[J].Lancet Oncol,2011,12(8):735-742.doi:10.1016/S1470-2045(11)70184-X.
  • 5Mok TS,Wu Y,Nakagawa K,et al.Gefitinib/chemotherapy vs. chemotherapy in epidermal growth factor receptor(EGFR)muta- tion positive non-small cell lung cancer(NSCLC)after progression on first-line gefitinib:The phase DI,randomised IMPRESS study[C]//2014 ESMO Annual Meeting Proceedings.Madrid,2014.
  • 6Gazdar AF.Activating and resistance mutations of EGFR in non-small-cell lung cancer:role in clinical response to EGFR tyrosine kinase inhibitors[J].Oncogene,2009,28(Suppl I):S24-S31.doi:10.1038/onc.2009.198.
  • 7Park K,Ahn M,Yu C,et al.ASPIRATION:firet-line erlotinib(E) until and beyond RECIST progression(PD)in Asian patients(pts) with EGFR mutation-positive(mut+)NSCLC[C]//2014 ESMO Annual Meeting Proceeding.Madrid,2014.
  • 8Jadad A R,Moore R A,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary?[J].Controlled Clinical Trials,1996,17(1):1-12.
  • 9Miller VA,Hirsh V,Cadranel J,et al.Afatinib versus pla- cebo for patients with advanced,metastatic non--small- cell lung cancer after failure of erlotinib,gefitinib,or both, and one or two lines of chemotherapy(LUX-Lung I):a phase 2b/3 randomised trial[J].Lancet Oncol,2012,13(5):528-538.doi:10.1016/S1470-2045(12)70087-6.
  • 10Yang JC,Hirsh V,Schuler M,et al.Symptom control and quality of life in LUX-Lung 3:a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung ad- enocarcinoma with EGFR mutations[J].J Clin Oncol,2013,31(27):3342-3350.doi:10.1200/jc0.2012.46.1764.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部